MIRM - Mirum Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

MIRM is currently covered by 9 analysts with an average price target of $66.61. This is a potential upside of $22.34 (50.46%) from yesterday's end of day stock price of $44.27.

Mirum Pharmaceuticals's activity chart (see below) currently has 77 price targets and 115 ratings on display. The stock rating distribution of MIRM is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 52.95% with an average time for these price targets to be met of 600.75 days.

Highest price target for MIRM is $74, Lowest price target is $39, average price target is $59.78.

Most recent stock forecast was given by ED ARCE from HC WAINWRIGHT on 28-Feb-2025. First documented stock forecast 12-Aug-2019.

Currently out of the existing stock ratings of MIRM, 61 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$72

$28.31 (64.80%)

$66

2 months 12 days ago
(28-Feb-2025)

3/29 (10.34%)

$24.43 (51.36%)

1048

Buy

$55

$11.31 (25.89%)

$50

2 months 13 days ago
(27-Feb-2025)

7/8 (87.5%)

$8.02 (17.07%)

354

Buy

$74

$30.31 (69.38%)

$69

2 months 16 days ago
(24-Feb-2025)

0/11 (0%)

$23.05 (45.24%)

Buy

$68

$24.31 (55.64%)

$64

5 months 27 days ago
(13-Nov-2024)

4/6 (66.67%)

$24.08 (54.83%)

337

Buy

$49

$5.31 (12.15%)

$46

6 months 23 days ago
(17-Oct-2024)

12/12 (100%)

$9.68 (24.62%)

659

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is MIRM (Mirum Pharmaceuticals) average time for price targets to be met?

On average it took 600.75 days on average for the stock forecasts to be realized with a an average price target met ratio 52.95

Which analyst has the current highest performing score on MIRM (Mirum Pharmaceuticals) with a proven track record?

ED ARCE

Which analyst has the most public recommendations on MIRM (Mirum Pharmaceuticals)?

Ed Arce works at HC WAINWRIGHT and has 26 price targets and 16 ratings on MIRM

Which analyst is the currently most bullish on MIRM (Mirum Pharmaceuticals)?

Yasmeen Rahimi with highest potential upside - $33.31

Which analyst is the currently most reserved on MIRM (Mirum Pharmaceuticals)?

Jessica Fye with lowest potential downside - -$4.69

Mirum Pharmaceuticals in the News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., May 09, 2025–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 9, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,230 shares of common stock and 26,585 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement...

Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL

– 28-week data from the Phase 2b VANTAGE PBC study highlights statistically significant improvements in pruritus and numeric improvements in fatigue, the two most burdensome symptoms of PBC – Seventy percent of patients treated with volixibat experienced a ≥50% reduction in serum bile acids – Volixibat treated patients experienced reductions in IL-31 FOSTER CITY, Calif.,...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?